Bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Severe vaso-occlusive events were eliminated for 94% of evaluable patients and all VOEs were eliminated for 88% of evaluable patients between 6 and 18 months post-infusion


LYFGENIA is the most...

Related Keywords

Alabama ,United States ,America ,Andrew Obenshain ,John Tisdale ,Regina Hartfield ,Julie Kanter ,Youtube ,Sickle Cell Disease Association Of America Inc ,National Heart ,Instagram ,Molecular Therapeutics Branch ,Division Of Hematology ,Exchange Commission ,Blood Institute ,Treatment Centers Qtcs ,National Institutes Of Health ,Linkedin ,Drug Administration ,Nasdaq ,Sickle Cell Disease Association ,Alabama Birmingham Adult Sickle Cell Clinic ,National Institutes ,Qualified Treatment Centers ,Priority Review ,Rare Pediatric Disease Priority Review Voucher ,Data Supporting Approval ,Safety Information ,Boxed Warning ,Marketing Long Term Follow Up Study ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Rev Dis ,Markets ,